Why Your Biohacking Clinic Is Losing High-Intent Leads (the Leaky-Bucket Problem)
Prime Therapeutics reports 47 percent of members still on a GLP-1 for weight loss at 180 days and 15 percent at two years. A JAMA Network Open cohort of 125,474 adults found 64.8 percent of patients without type 2 diabetes discontinued within one year. A longevity clinic does not usually lose a high-intent lead at the front door. It loses her in the lapse window, and the window is datable.
Ed
Biohacking / Longevity, Pillar 1, Revenue Recovery Infrastructure, lead recovery
General information for practice owners, not medical, legal or tax advice.
A biohacking or longevity clinic does not usually lose a high-intent lead at the front door. It loses her at the second appointment, and two independent bodies of data name the same window. Prime Therapeutics, a pharmacy benefit manager reporting on commercially insured members without diabetes who started a GLP-1 receptor agonist for weight loss, found 47 percent still on therapy at 180 days, 29 percent at one year and 15 percent at two years [1]. A retrospective cohort of 125,474 US adults published in JAMA Network Open in January 2025 found that 64.8 percent of patients without type 2 diabetes discontinued semaglutide, tirzepatide or liraglutide within one year [2]. Those are the populations a longevity panel is drawn from.
That is a structural fact about the treatment category. It is not a claim about any clinic's revenue, and this post makes none. It is also why the leaky-bucket framing belongs on a longevity practice rather than a retail funnel: the acquisition already worked. She answered the ad, booked the consult and paid. What fails afterwards is the follow-up structure, which is a question of who reaches out, when, and about what. Below are the leak points, the rules that govern reaching a lapsed client, and the four numbers to measure before spending anything on more leads.
The leak is a lapse window, not a lead-capture failure
In the Prime Therapeutics analysis, more than half of the starting cohort was off therapy inside six months [1]. In the JAMA Network Open cohort, nearly two thirds of patients without type 2 diabetes were off therapy inside twelve [2]. Neither figure describes people who never converted. It describes people who converted, paid, started, and then stopped. A practice that responds to that pattern by buying more leads is refilling a bucket rather than finding the hole.
The same peer-reviewed cohort found that weight regain was significantly associated with reinitiation [2]. That is the operationally useful part: a measurable share of lapsed patients come back, and the return is triggered by something that happens weeks or months after the practice stops paying attention. Nothing in a typical practice notices it. This is the dormancy mechanism examined in more detail in our analysis of biomarker interpretation coaching loops.
A regulatory event, not attrition, emptied many GLP-1 programs in 2025
On 21 February 2025 the U.S. Food and Drug Administration determined that the semaglutide shortage was resolved. The agency then set two dated cutoffs for compounders operating under the shortage exemption: state-licensed pharmacies compounding under section 503A had until 22 April 2025, and outsourcing facilities under section 503B had until 22 May 2025 [3]. Tirzepatide had already come off the shortage list in December 2024, with its own compounding cutoffs.
For any longevity or weight-management practice whose program ran on compounded semaglutide, that is a supply line that ended on a published date, not a gradual decline in patient interest. It produces a lapse cohort with a known start. If a clinic has never segmented that cohort, it is carrying a group of former patients who did not choose to leave.
A cash-pay longevity clinic can sit outside HIPAA and still owe breach notice to the FTC
HIPAA defines a covered entity at 45 CFR 160.103 as a health plan, a health care clearinghouse, or a health care provider who transmits health information in electronic form in connection with a transaction covered by the rule [4]. A pure cash-pay practice that bills no insurance may therefore fall outside that definition, which is where many longevity clinics assume the analysis stops.
It does not. The Federal Trade Commission's Health Breach Notification Rule at 16 CFR Part 318 reaches vendors of personal health records and related entities that are not covered by HIPAA. The FTC's amendments, published in the Federal Register on 30 May 2024 and effective 29 July 2024, were written specifically to clarify that the rule covers developers of health applications and similar technologies [5]. A client portal, a wearable integration or a reactivation database at a non-covered clinic is squarely in scope. If your practice does handle records under a prescribing medical director, the controls to verify before any automation touches them are set out in our Discretion standard.
Reaching a lapsed client is governed by 47 CFR 64.1200, not by your CRM settings
A reactivation cadence is outbound contact, so the Telephone Consumer Protection Act rules apply. Two provisions of 47 CFR 64.1200 decide how the cadence has to be built [6]:
A caller must honor a revocation request within a reasonable time, and that period may not exceed ten business days from receipt of the request.
A caller may not designate an exclusive means of revoking consent. A client who says stop on a voice call has revoked, whether or not she used the word in a text reply.
This is why a reactivation cadence is an infrastructure question rather than a marketing one. The revocation path has to be wired into the same system that sends the touches, before the first touch goes out.
A re-engagement cadence should be defined as actions, on a clock, not as outcomes
An AI voice agent can run a defined cadence, for clients who have consented to it, as an auxiliary layer behind the clinical team, not a replacement for it. Stated as actions rather than results:
Week 2 after the first visit: an AI-disclosed check-in call that asks how the client is doing and whether she has questions for the clinical team.
Week 6: an invitation to discuss other services with your clinician, using wording your clinical team approves.
Week 10: an invitation to schedule a twenty-minute consult with a clinician to map a longer plan.
Quarterly thereafter: a brief check-in, with a documented revocation path on every touch.
Re-engagement runs only for patients who have given the practice prior express written consent to automated or AI calls and texts, and, where a message promotes a service, HIPAA marketing authorization. Every call opens by saying it is an AI assistant and that the call is recorded. Every text carries "Reply STOP to opt out," and any reasonable opt-out is honored across all channels. Calls go out Monday through Saturday, 10 a.m. to 5 p.m. in the recipient's local time, at most three attempts in 24 hours, and not at all in states where AI-voice outreach of this kind is restricted. No one is contacted without that consent, and TTR never runs cold outreach. Outbound is a Standing Watch capability; First Watch makes no outbound calls.
The reason this is automation work rather than staffing work is not a claim about how many patients a coordinator can hold. It is that the cadence has to fire on a clock for every patient, including the ones who have gone quiet, and quiet patients are the ones a busy human list stops reaching first.
Four numbers to pull from your own records this week
These are measurements of your practice, from your systems. They are not estimates and this post supplies no benchmark to compare them against.
Distinct services used per active client over the last twelve months, as a distribution rather than an average.
Days since last completed visit, for every client on the panel, as a distribution. Look for where it clusters.
The count of clients whose last therapy was a compounded GLP-1 dispensed before the April and May 2025 cutoffs [3]. That is a lapse cohort with a documented cause.
Your measured elapsed time from a revocation request to the last message sent, in business days, against the ten-day ceiling in 47 CFR 64.1200 [6].
If the second number clusters heavily past ninety days and the third is not zero, the gap is in follow-up structure rather than acquisition. You can book a working session to map a cadence to your own panel.
References
[1] Prime Therapeutics. "Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years." primetherapeutics.com
[2] Rodriguez PJ, et al. "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity." JAMA Network Open. 2025;8(1):e2457349. PubMed 39888616
[3] U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." fda.gov
[4] 45 CFR 160.103, definition of "covered entity." eCFR
[5] Federal Trade Commission. Health Breach Notification Rule, 16 CFR Part 318. Final amendments published 30 May 2024, effective 29 July 2024. Federal Register
[6] 47 CFR 64.1200, revocation of consent. eCFR
Next Step
If your premium practice runs more than 100 inbound consult inquiries a month and has no structured measurement of how many never reach a scheduled consultation, your pipeline may be leaking revenue you cannot see. The Line Audit shows you what actually happens: we call your line at the hours you're least likely to answer and send you the recordings with a written breakdown.
Audit Real-Time Conversational Velocity: Talk to Rosey, our AI receptionist, at +1 (720) 776-1664 (an AI demo line; calls are recorded).
